Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MediPharm Labs introduces CBD 100, THC 30 and the company’s first cannabinoid cannabinol (CBN) rich formula
  • MediPharm has also launched its next-generation oil products with its first unique CBN formula, CBN1:2 Nighttime Formula containing 10mg/ml of CBN and 20mg/ml of THC
  • These products will be available through retail channels in Ontario, British Columbia, Alberta, Manitoba and Saskatchewan
  • MediPharm Labs specializes in the production of pharmaceutical quality cannabis oil and concentrates
  • MediPharm Labs Corp. (LABS) is unchanged on the day, trading at C$0.47 per share at 11:00 am ET

MediPharm Labs Corp. (LABS) has launched CBD 100, THC 30 and the company’s first cannabinoid cannabinol (CBN) rich formula.

“MediPharm Labs is dedicated to developing innovative and customized formulated products that consumers can trust for their individual medicinal and wellness needs,” said Keith Strachan, President and Interim CEO, MediPharm Labs.

“Our latest release of new cannabinoid-based formulas, including our first formulation of minor cannabinoid CBN, enables us to fulfill increasing customer demand for more personalized products while maintaining our commitment to pharma-quality manufacturing.”

These new products are the latest in MediPharm Labs’ family of branded products, delivering a unique flavour profile from the naturally occurring cannabis terpenes, each using coconut/palm-based MCT carrier oil carefully chosen for sustainable practices and each produced according to our exacting manufacturing standards to ensure the highest purity and quality.

The new products include CBD100 Ultra Formula oil, containing the highest amount of CBD currently available at 100mg/ml and THC30 Plus Formula oil, containing 30mg/ml, the most potent format available under Health Canada’s regulations.

MediPharm also launched its next-generation oil products with its first unique CBN formula, CBN1:2 Nighttime Formula containing 10mg/ml of CBN and 20mg/ml of THC using full spectrum cannabis concentrate CBN.

CBN is typically found in only trace quantities in the cannabis plant but can be formed through the oxidation of THC.

Initial quantities will be available in the coming weeks for patients through Medical Cannabis by Shoppers and for consumers through retail channels in Ontario, British Columbia, Alberta, Manitoba and Saskatchewan.

MediPharm Labs plans to achieve full national distribution of its full suite of cannabis products becoming a “One-Stop-Shop” for retailers and distributors across Canada.

MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates.

MediPharm Labs Corp. (LABS) is unchanged on the day, trading at C$0.47 per share at 11:00 am ET.

More From The Market Herald

" Israeli Technology company BYND Cannasoft (CSE:BYND) acquires Zigi Carmel Investments Ltd.

BYND Cannasoft (BYND) closes the acquisition of Zigi Carmel Investments with a value of US $28 million.

" The Market Herald’s Weekly Cannabis Report – Sept 23, 2022

Cannara Biotech (TSXV:LOVE) has entered British Columbia’s marketplace and has launched its first two premium products in the vape and accessory categories.
The Gummy Project to serve Vancouvers Shakespeare Festival

" The Gummy Project (CSE:GUMY) expands in U.S. after receiving purchase order from a 5-star luxury hotel

The Gummy Project (GUMY) has received a purchase order from the 5-star luxury Four Seasons Hotel San Francisco.

" Nextleaf (CSE:OILS) launches new cannabis brand, High Plains

Nextleaf Solutions (OILS) has launched its new cannabis brand, High Plains.